INFORMAZIONI PERSONALI

Nome	**Mancuso Maria Elisa**
Data di nascita	29.11.1975
Qualifica	Medico
Amministrazione	
Incarico attuale	Dirigente Medico di I livello
Numero telefonico dell'ufficio	0255034072
Fax dell'ufficio	0255032072
E-mail istituzionale	mariaelisa.mancuso@policlinico.mi.it

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Laurea in Medicina e Chirurgia
Altri titoli di studio e professionali	Specializzazione in Ematologia Dottorato di Ricerca in Metodologia Clinica
Esperienze professionali (incarichi ricoperti)	Incarico di ricerca presso la Fondazione PoliMaRe dal 2004 al 2007 Dirigente Medico di I Livello presso la Fondazione PoliMaRe dal 2008
Capacità linguistiche	Italiano, Inglese, Francese
Capacità nell'uso delle tecnologie	Buona
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazioni a riviste; ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)	**Pubblicazioni - Articoli originali** G. Mancuso, C. Scalici, R. Potenzano, ***M.E. Mancuso***. "Congenital afibrinogenemia." Ital J Pediatr 2003; 29: 157-160 G.A. Piccillo, A. Musco, ***M.E. Mancuso***, E.G. Mondati. "A catastrophic case of skin gangrene." Ann Ital Med Int 2005 Jan-Mar; 20 (1): 51-3 E. Santagostino, ***M.E. Mancuso***, A. Rocino, G. Mancuso, M.G. Mazzucconi, A. Tagliaferri, M. Messina, P.M. Mannucci. "Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study." Br J Haematol 2005; 130: 422-27 A. Tripodi, ***M.E. Mancuso***, V. Chantarangkul, M. Clerici, R. Bader, P.L.

Meroni, E. Santagostino, P.M. Mannucci. "Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII. Considerations on the differentiation between the two circulating anticoagulants." Clin Chem 2005; 51: 1883-5

E. Santagostino, ***M.E. Mancuso***, A. Rocino, G. Mancuso, F. Scaraggi, P.M. Mannucci. "A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors." J Thromb Haemost 2006; 4: 367-71

AB. Federici, E. Santagostino, MG. Rumi, A. Russo, ***M.E. Mancuso***, R. Soffredini, PM. Mannucci, M. Colombo. "The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study." Haematologica 2006; 91: 503-8

A..Rocino, E. Santagostino, ***M.E. Mancuso***, PM. Mannucci. "Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors." Haematologica 2006; 91: 558-61

E. Santagostino, ***M.E. Mancuso***, M. Morfini, M. Schiavoni, A. Tagliaferri, G. Barillari, PM. Mannucci. "Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy." Haematologica 2006; 91: 634-9

C. Negrini, F. Daniele, ***M.E. Mancuso***, GF. Rivolta, A. Tagliaferri. "Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura." Pharmacoeconomics - Italian Research Articles 2006; 8(1): 1-12

M.E. Mancuso, M.G. Rumi, E. Santagostino, S. Linari, A. Coppola, P.M. Mannucci, M. Colombo for the Hepatitis Study Group of the Association of Italian Hemophilia Centers. "High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C." Haematologica 2006; 91: 1367-71

S.C. Gouw, J.G. van der Bom, H.M. van den Berg for the CANAL Study Group (with ***M.E. Mancuso***). "Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study." Blood 2007; 109: 4648-54

S.C. Gouw, J.G. van der Bom, G. Auerswald, C. Escuriola Ettinghausen, U. Tedgard, H.M. van den Berg for the CANAL Study Group (with ***M.E. Mancuso***). "Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study." Blood 2007; 109: 4693-7

M.E. Mancuso, P.M. Mannucci, A. Sartori, A. Agliardi, E. Santagostino. "Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters." Br J Haematol 2008; 141:689-95

G. Pasta, A. Forsyth, CR. Merchan, SMJ. Mortazavi, M. Silva, K. Mulder, ***E. Mancuso***, O. Perfetto, M. Heim, H. Caviglia, L. Solimeno. Orthopaedic management of haemophilia arthropathy of the ankle. Haemophilia 2008; 14 (Suppl 3): 170-6.

E. Santagostino, ***M.E. Mancuso***. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus 2008; 6 (suppl 2): s12-s16.

P.C. ter Avest, K Fischer, ***M.E. Mancuso***, E. Santagostino, V. Jiménez Yuste, HM van den Berg, JG van der Bom. Risk stratification for inhibitor development at first treatment for severe haemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.

E. Santagostino, ***M.E. Mancuso***. Prevention of arthropathy in haemophilia: prophylaxis. Haemophilia 2008; 14 (suppl 6): 16-19.

G. Pasta, ***M.E. Mancuso***, O.S. Perfetto, L.P. Solimeno. Synoviorthesis in haemophilia patients with inhibitors. Haemophilia 2008; 14 (suppl 6): 52-55.

M.E. Mancuso, L. Graca, G. Auerswald, E. Santagostino. Haemophilia care in children – benefits of early prophylaxis for inhibitor prevention. Haemophilia 2009; 15 (suppl 1): 8-14.

Biguzzi E, Mancuso P, Franchi F, Calleri A, ***Mancuso ME***, Santagostino E, Bucciarelli P, Bertolini F, Mannucci PM. Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical

phenotype. Br J Haematol 2009; 144: 803-5.
L.P. Solimeno, ***M.E. Mancuso***, G. Pasta, E. Santagostino, S. Perfetto, P.M. Mannucci. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol 2009; 145: 227-34.
M.E. Mancuso, L. Berardinelli, C. Beretta, M. Raiteri, E. Pozzoli, E. Santagostino. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 2009; 94: 687-92.
Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, ***Mancuso ME***, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM. Comparison of the rates of joint arthroplasty in patients with severe factro VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders. Blood 2009; 114: 779-84.
Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G for the AICE PROFIT Study Group (with ***Mancuso ME***). Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
Castaman G, ***Mancuso ME***, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, Rodeghiero F. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost 2009; 7: 1824-31.
M.E. Mancuso, M.G. Rumi, A. Aghemo, E. Santagostino, M. Puoti, A. Coppola, M. Colombo, P.M. Mannucci. Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. J Thromb Haemost 2009; 7: 1997-2005
G. Pasta, ***M.E. Mancuso***, O.S. Perfetto, L.P. Solimeno. Radiosynoviorthesis in childrren with haemophilia. Hämostaseologie 2009; 29 (Suppl 1): S62-S64
E. Santagostino, ***M.E. Mancuso***. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16 (Suppl 1), 20-24
M.E. Mancuso, L. Berardinelli. Arteriovenous fistula as stable venous access in children with severe haemophilia. Haemophilia 2010; 16 (Suppl 1), 25-28

Data: 10 novembre 2017



© Unione europea, 2002-2017 | europass.cedefop.europa.eu